Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- Chuikyo to Resume Discussions on Diovan Ads’ Impact on Healthcare Finances
June 27, 2014
- MHLW to Conduct Hearings over CASE-J Study, Take “Appropriate Action” against Takeda: Minister
June 27, 2014
- Drugs under Simultaneous Global Development May also Be Eligible for New Fast-Track Review System: MHLW Exec
June 26, 2014
- Govt Approves Economic Strategies, Chuikyo Likely to Discuss NHI Price Revision Frequency
June 25, 2014
- Ryukaikon to Meet on July 2; FY2013 Price Settlement Rates to Be Reported
June 25, 2014
- MHLW Issues Notification on Electronic Applications
June 24, 2014
- Blopress Excluded from Generic Share Calculation until September
June 23, 2014
- Broad Perspective Important for Vaccination Policy: CDC Official
June 23, 2014
- LDP OKs Revised Version of Draft Economic, Fiscal Policy Guidelines
June 20, 2014
- First Generics of Diovan, Blopress AGs Join Reimbursement List
June 20, 2014
- PAFSC’s Second Committee to Discuss Approval for IFN-Free Hepatitis C Treatments on June 26
June 19, 2014
- Drug Price Settlement Rate for March 2014 at 98.4%: MHLW
June 19, 2014
- LDP Members Request Govt to Stay with Current Biennial NHI Price Revision
June 18, 2014
- MHLW on Tap to Launch Expedited Drug Review System in 2015
June 18, 2014
- Govt Weighs Applying Mixed Care Scheme to Low Cost-Effective Drugs: Draft Growth Strategy
June 17, 2014
- PMDA Reviewing Osteoporosis Treatment Forteo for Risk of Shock, Anaphylaxis
June 17, 2014
- “Annual” NHI Price Revision Erased from Gov’t Draft Policy Blueprint
June 16, 2014
- Regulatory Reform Proposal Including Expansion of Mixed Care Use Submitted to Prime Minister
June 16, 2014
- LDP Members with Vested Interests Slam Annual NHI Price Revision
June 12, 2014
- MHLW Panel OKs Draft Report on Medical Database Project, but Further Discussion Needed for Drug Makers’ Usage
June 12, 2014
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…